Ask anyone who has tried to start Wegovy or Zepbound through insurance and you may hear about the same gatekeeper: prior authorization, the paperwork step where a health plan decides whether it will pay before the first prescription is filled. A new analysis presented at ObesityWeek 2026, The Obesity Society’s annual meeting, puts hard numbers on how that gate works in practice. Of 69,462 patients with prior authorization submissions to begin semaglutide or tirzepatide treatment, 35.7% had their requests denied. And the data suggest that Wegovy prior authorization outcomes depended more on the payer, pharmacy benefit manager and region than on the patient characteristics researchers measured.
The study, by Broffman and colleagues and summarized by The American Journal of Managed Care (AJMC) on November 14, used deidentified clinical and insurance records from a telehealth platform. It covered commercially insured adults aged 18 to 63 who met clinical criteria for obesity treatment and whose medication benefits were checked between January 1 and September 30, 2025. That makes it a large real-world look at what happens between clinical eligibility for an obesity drug and a plan’s decision about coverage.
Wegovy prior authorization is the rule, not the exception
The first finding is how rarely these drugs were covered without additional authorization. Among 225,000 randomly selected patients whose benefits were checked, coverage without prior authorization was identified for just 3.7% of semaglutide checks and 2.8% of tirzepatide checks. Coverage requiring prior authorization was identified for 35.7% and 31.1%, respectively. Another 27.0% of benefit checks were indeterminate.
Those figures do not mean that every remaining patient faced a prior authorization requirement. Some coverage was excluded, restricted or could not be established from the available information. But the overall picture was clear: straightforward access without an authorization step was uncommon in this population.
Once a treatment-initiation prior authorization was submitted, the results divided sharply. Among 69,462 patients with submissions, 53.2% had approved requests, 35.7% had denied requests and 11.2% had unknown outcomes. The unknown category matters. Those cases should not be counted as approvals or denials, nor treated as evidence that patients ultimately received medication.
More than one in three recorded initiation requests being denied is a substantial barrier for a class of medicines used to treat a chronic disease. A prescription and clinical eligibility, the analysis suggests, were not enough to guarantee insurance coverage.
For many patients in this dataset, qualifying for treatment was only the beginning. Insurance coverage was a separate decision.

Why the requests were denied
The denial reasons are where the study becomes a story about insurance benefit design rather than simply another access statistic. Just over half of recorded denials, 51.1%, involved plan exclusions or coverage limitations. Another 24.7% were attributed to unmet clinical eligibility criteria, such as BMI, diagnosis or comorbidity requirements. A further 12.7% involved unmet therapy requirements, including requirements to try another treatment first.
Put plainly, the largest recorded category of denial was not a finding that a patient failed the study’s broad clinical eligibility criteria. It was that their particular health plan excluded or restricted coverage. That distinction matters because a patient may qualify for an FDA-approved treatment while still facing a separate, narrower set of insurance rules.
Denial rates were highest, at 38.7%, among patients with a body mass index between 27.0 and 29.9 and at least one obesity-related condition. That group falls within the usual adult weight-management eligibility framework for these medicines when an appropriate accompanying condition is present. Among denials in this BMI category, 41.7% were attributed to unmet clinical eligibility criteria. At the other end of the BMI spectrum, plan exclusions or coverage limitations accounted for 56.7% of denials among patients with a BMI of 40 or higher.
The authors also reported that benefits-verification and prior authorization outcomes varied more by payer or pharmacy benefit manager and geographic region than by patient demographics or measured clinical characteristics. That is an important observation, though it does not establish that every denial was unrelated to medical considerations. The study was observational, and coverage criteria themselves can incorporate clinical information.
What it does establish is that the insurance arrangement surrounding a patient can be a major influence on whether a requested obesity treatment is covered. Two people with similar clinical characteristics may face different benefit rules, and the analysis found that those differences mattered.
It fits a pattern seen at the pharmacy counter
The ObesityWeek findings fit a broader pattern seen in earlier national pharmacy claims research. A JAMA study published July 9, 2026, led by Joseph Levy of the Johns Hopkins Bloomberg School of Public Health, examined more than 2 million initial attempts to fill single-source branded prescriptions between 2018 and 2024.
Weight-management incretin products had the lowest initial payment rate among the major drug classes in the study. Only 14.8% of attempted first fills in that category were initially paid. Another 44.5% were rejected for formulary exclusion and 40.6% for utilization management requirements, such as prior authorization or step therapy.
Across all the branded drug classes studied, 38.6% of prescriptions initially rejected were subsequently filled with the originally prescribed medicine within 90 days. Another 13.0% resulted in a different medicine from the same therapeutic class, while 48.4% had no recorded fill from that class during the follow-up period. Those follow-up percentages describe the overall branded-drug sample, not specifically weight-management incretins.
The two studies measure different stages of access. Broffman and colleagues examined benefits verification and prior authorization for obesity treatment. Levy and colleagues examined initial pharmacy claims and subsequent dispensing across multiple insurance types and drug classes. Their percentages cannot be compared as though they measure the same outcome.
Nevertheless, both point to the practical importance of formulary rules. Access restrictions may appear when a clinician seeks authorization or when a patient tries to fill an approved prescription. They can create delays, require additional paperwork or prevent a medicine from being dispensed through insurance.
Grey Pepper has tracked this tension in its reporting on employer GLP-1 coverage decisions for 2027 and the federal push for greater transparency around pharmacy benefit manager fees. Both stories help explain why a drug’s medical value and its availability through a particular employer or insurer can remain separate questions.
For obesity medicines, the treatment decision may begin in the doctor’s office. The coverage decision often depends on rules written elsewhere.
What the data cannot tell us
There are important limits to this evidence. The Broffman analysis used clinical and insurance records from a telehealth platform, so its participants were people seeking treatment through that setting. The sample may not represent everyone who visits a primary care physician or obesity specialist. Its observation period ended in September 2025, meaning the findings do not describe every insurance policy in effect during 2026.
The published AJMC summary also does not identify the individual insurers or pharmacy benefit managers with the highest denial rates. Nor does it show what happened to every denied patient after an appeal, a new prescription or a decision to pay out of pocket. The 11.2% of authorization submissions with unknown outcomes leave another important gap in the record.
The source and commercial context also deserve attention. AJMC reported that the observational analyses in its ObesityWeek roundup included coauthors affiliated with Amgen, a pharmaceutical company developing obesity treatments. That affiliation does not invalidate the findings, but it is relevant when evaluating industry-linked research into access barriers and the financial burden of obesity treatment.
A separate analysis presented in the same roundup, by Cai and colleagues, examined 27,013 adults with obesity or overweight who initiated injectable semaglutide or tirzepatide. Only 41.9% remained on their initial treatment for at least 12 months without a gap exceeding 60 days.
After statistical adjustment, patients who persisted on treatment had mean medical costs $1,422 to $2,400 lower over the subsequent six months than groups who discontinued earlier. They also had fewer emergency department visits and inpatient admissions.
Those findings are associations, not proof that continuing GLP-1 treatment caused the lower costs or utilization. The analysis also excluded pharmacy spending, a central part of the financial equation for employers and insurers. It therefore cannot establish that broader drug coverage would pay for itself.
Why it matters now
The debate over obesity drugs has often focused on price: what manufacturers charge, what patients pay in cash and whether employers can afford widespread coverage. Those questions remain important. But the ObesityWeek data highlight another barrier that can persist even as prices and purchasing options change: the plan’s decision about which treatments it will cover and under what conditions.
For insured patients, a lower cash price does not necessarily translate into coverage through a prescription benefit. A medicine can remain subject to prior authorization, step therapy or an outright exclusion. Whether shifts in pricing will change those restrictions in 2027 is a question for future plan decisions, not an answer established by this study.
For patients, the practical message is that a denial may reflect a policy restriction rather than a conclusion that treatment is medically inappropriate. The reason given in the denial notice matters. Patients and clinicians may need to distinguish missing documentation, unmet plan criteria and benefit exclusions before determining whether clarification or an appeal is possible.
For policymakers and employers, the larger question is whether insurance rules are appropriately balancing clinical evidence, patient access and the cost of treatment. A prior authorization process can serve legitimate purposes, including confirming appropriate use. But the same process can also block or delay access when coverage conditions diverge from clinical eligibility.
The most telling result from the Broffman analysis is not simply that 35.7% of initiation requests were denied. It is that plan exclusions and coverage limitations were the single largest stated reason. The study reveals a gap between qualifying for a treatment and having an insurer agree to pay for it.
That gap is easy to overlook in a market defined by drug launches, weight-loss outcomes and price announcements. Yet for patients trying to obtain a prescription, the defining decision may still come from the insurance benefit design they never chose and may barely understand.
Sources
- The American Journal of Managed Care — ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity’s Costs, November 14, 2026. Includes the Broffman and Cai study summaries.
- Broffman L, Smith BJ, Manalac R, et al. Clinical eligibility and coverage gaps for GLP-1–based receptor agonists in patients with obesity. Presented at ObesityWeek 2026, November 14–17, 2026. ObesityWeek poster directory, Poster 531.
- Levy JF, Alexander GC, Vabson B, Ippolito BN. Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States. JAMA. Published online July 9, 2026; 336(8):664–672.
- PharmaVoice — Brand-name drug denials are surging, especially for weight-loss, July 28, 2026.
- Grey Pepper — The Employer GLP-1 Squeeze: Coverage Is Common, Confidence Is Not, October 30, 2026.
- Grey Pepper — Drug Middlemen Face a New Disclosure Rule. Employers May Finally See the Rebate Machinery, October 31, 2026.

